Bcr-Abl
Bcl-Abl is a constitutively activated chimeric tyrosine kinase which is the genetic abnormality expressed in patient with CML (chronic myeloid leukemia).
Products Related to Bcr-Abl(72)
- GC13343Bosutinib (SKI-606)CAS: 380843-75-4Purity: >99.50%
Bosutinib (SKI-606) is an oral Src/Abl tyrosine kinase inhibito with IC50 of 1.2 nM and 1 nM, respectively.
- GC15197Saracatinib (AZD0530)CAS: 379231-04-6Purity: >99.00%
Saracatinib (AZD0530) (AZD0530) is a potent Src family inhibitor with IC50s of 2.7 to 11 nM for c-Src, Lck, c-YES, Lyn, Fyn, Fgr, and Blk. Saracatinib (AZD0530) shows high selectivity over other tyrosine kinases.
- GC10314Imatinib (STI571)CAS: 152459-95-5Purity: >99.50%
Imatinib (STI571) (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively. Imatinib (STI571) also is an inhibitor of SARS-CoV and MERS-CoV.
- GC10915GZD824CAS: 1421783-64-3Purity: >99.00%
Olverembatinib (GZD824) dimesylate is a potent and orally active pan-Bcr-Abl inhibitor. GZD824 potently inhibits a broad spectrum of Bcr-Abl mutants. GZD824 strongly inhibits native Bcr-Abl and Bcr-AblT315I with IC50s of 0.34 nM and 0.68 nM, respectively. GZD824 has antitumor activity.
- GC11759Imatinib Mesylate (STI571)CAS: 220127-57-1Purity: >99.00%
Imatinib Mesylate (STI571) is an orally bioavailable multi-target inhibitor with IC 50 values for Bcr-Abl, c-Kit and PDGFR are 0.6μM, 0.1μM and 0.1μM respectively.
- GC14075NocodazoleCAS: 31430-18-9Purity: >98.00%
Nocodazole is an anti-mitotic drug and a rapid and reversible microtubule polymerization inhibitor. It inhibits Abl, Abl (E255K), and Abl (T315I) in cell-free assays with IC 50 values of 0.21μM, 0.53μM, and 0.64μM, respectively.
- GC14129Nilotinib(AMN-107)CAS: 641571-10-0Purity: >99.50%
Nilotinib(AMN-107) is a selective oral tyrosine kinase inhibitor that inhibits the autophosphorylation of native Bcr-Abl (WT p210) and mutant Bcr-Abl (E281K, E292K, F317L, M351T, and F486S) with IC 50 values of 20, 42, 31, 38, 29, and 41nM, respectively.
- GC14396Ponatinib (AP24534)CAS: 943319-70-8Purity: >99.00%
Ponatinib (AP24534) (AP24534) is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively.
| Catalog No. | Product Name | CAS No. | Purity | Structure |
|---|---|---|---|---|
| GC10858 | GNF 2 | 778270-11-4 | >98.00% | |
Bcr-Abl inhibitor | ||||
| GC12172 | 1-Naphthyl PP1 | 221243-82-9 | >98.50% | |
Src family kinases inhibitor | ||||
| GC12637 | PD 180970 | 287204-45-9 | >98% | |
P210bcr/abl tyrosine kinase inhibitor | ||||
| GC12779 | PPY A | 875634-01-8 | >98% | |
Abl kinases inhibitor | ||||
| GC13343 | Bosutinib (SKI-606) | 380843-75-4 | >99.50% | |
Bosutinib (SKI-606) is an oral Src/Abl tyrosine kinase inhibito with IC50 of 1.2 nM and 1 nM, respectively. | ||||
| GC13592 | PD173955 | 260415-63-2 | >99.00% | |
Dual Src/Abl kinase inhibitor, ATP-competitive, | ||||
| GC15079 | GNF 5 | 778277-15-9 | >98.00% | |
Bcr-Abl inhibitor | ||||
| GC15197 | Saracatinib (AZD0530) | 379231-04-6 | >99.00% | |
Saracatinib (AZD0530) (AZD0530) is a potent Src family inhibitor with IC50s of 2.7 to 11 nM for c-Src, Lck, c-YES, Lyn, Fyn, Fgr, and Blk. Saracatinib (AZD0530) shows high selectivity over other tyrosine kinases. | ||||
| GC15579 | Adaphostin | 241127-58-2 | >98% | |
P210bcr/abl tyrosine kinase inhibitor | ||||
| GC10314 | Imatinib (STI571) | 152459-95-5 | >99.50% | |
Imatinib (STI571) (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively. Imatinib (STI571) also is an inhibitor of SARS-CoV and MERS-CoV. | ||||
| GC10607 | GNF-7 | 839706-07-9 | >98.50% | |
Type II Bcr-Abl inhibitor | ||||
| GC10638 | AT9283 | 896466-04-9 | >99.50% | |
A broad spectrum kinase inhibitor | ||||
| GC10914 | AST 487 | 630124-46-8 | >99.00% | |
A multi-kinase inhibitor | ||||
| GC10915 | GZD824 | 1421783-64-3 | >99.00% | |
Olverembatinib (GZD824) dimesylate is a potent and orally active pan-Bcr-Abl inhibitor. GZD824 potently inhibits a broad spectrum of Bcr-Abl mutants. GZD824 strongly inhibits native Bcr-Abl and Bcr-AblT315I with IC50s of 0.34 nM and 0.68 nM, respectively. GZD824 has antitumor activity. | ||||
| GC10970 | WP1130 | 856243-80-6 | >99.50% | |
WP1130 (WP1130) is a cell-permeable deubiquitinase (DUB) inhibitor, directly inhibiting DUB activity of USP9x, USP5, USP14, and UCH37. WP1130 has been shown to downregulate the antiapoptotic proteins Bcr-Abl and JAK2. | ||||
| GC11140 | Radotinib(IY-5511) | 926037-48-1 | >98% | |
Bcr-Abl tyrosine kinase inhibitor | ||||
| GC11737 | AG957 | 140674-76-6 | >98% | |
a tyrphostin that targets transforming Bcr-Abl fusion proteins | ||||
| GC11759 | Imatinib Mesylate (STI571) | 220127-57-1 | >99.00% | |
Imatinib Mesylate (STI571) is an orally bioavailable multi-target inhibitor with IC 50 values for Bcr-Abl, c-Kit and PDGFR are 0.6μM, 0.1μM and 0.1μM respectively. | ||||
| GC13102 | XL228 | 898280-07-4 | >99.00% | |
A tyrosine kinase inhibitor | ||||
| GC13914 | Flumatinib mesylate | 895519-91-2 | >99.50% | |
PDGRFβ inhibitor | ||||
| GC14075 | Nocodazole | 31430-18-9 | >98.00% | |
Nocodazole is an anti-mitotic drug and a rapid and reversible microtubule polymerization inhibitor. It inhibits Abl, Abl (E255K), and Abl (T315I) in cell-free assays with IC 50 values of 0.21μM, 0.53μM, and 0.64μM, respectively. | ||||
| GC14129 | Nilotinib(AMN-107) | 641571-10-0 | >99.50% | |
Nilotinib(AMN-107) is a selective oral tyrosine kinase inhibitor that inhibits the autophosphorylation of native Bcr-Abl (WT p210) and mutant Bcr-Abl (E281K, E292K, F317L, M351T, and F486S) with IC 50 values of 20, 42, 31, 38, 29, and 41nM, respectively. | ||||
| GC14237 | Nilotinib monohydrochloride monohydrate | 923288-90-8 | >99.50% | |
A Bcr-Abl inhibitor | ||||
| GC14396 | Ponatinib (AP24534) | 943319-70-8 | >99.00% | |
Ponatinib (AP24534) (AP24534) is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively. | ||||